RenovoRx Appoints Mark Voll as Chief Financial Officer for Commercial Growth

RenovoRx has appointed Mark Voll as Chief Financial Officer, effective February 1, 2026. Voll brings over three decades of financial leadership experience, with a strong track record in guiding high-growth public companies through commercial buildout and strategic development. He joins RenovoRx to support the company's commercial growth of RenovoCath, a patented, FDA-cleared drug-delivery device. Voll's appointment strengthens RenovoRx's C-suite leadership and positions the company for future growth.